Theriva Biologics, Inc. (TOVX) Earnings History
Annual and quarterly earnings data from 1993 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export TOVX earnings history in CSV or JSON format
Free sign-in required to download data
Theriva Biologics, Inc. (TOVX) Earnings Overview
As of March 4, 2026, Theriva Biologics, Inc. (TOVX) reported trailing twelve-month net income of -$26M, reflecting +0.3% year-over-year growth. The company earned $-2.71 per diluted share over the past four quarters.
Looking at the long-term picture, TOVX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$1M in fiscal 2005.
Theriva Biologics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including MCRB ($5M net income), PHGE (-$37M net income), ARMP (-$47M net income, -3.7% margin), TOVX has comparable earnings metrics. Compare TOVX vs MCRB →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
30 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$26M | -39.8% | -$26M | $-19.03 | - | - |
| 2023 | -$18M | +6.8% | -$21M | $-28.48 | - | - |
| 2022 | -$20M | -38.0% | -$22M | $-32.66 | - | - |
| 2021 | -$14M | -42.1% | -$14M | $-1.90 | - | - |
| 2020 | -$10M | +34.4% | -$10M | $-6.60 | - | - |
| 2019 | -$15M | -14.5% | -$16M | $-9.14 | - | - |
| 2018 | -$13M | +11.9% | -$18M | $-21.45 | - | - |
| 2017 | -$15M | +44.3% | -$26M | $-42.70 | - | - |
| 2016 | -$27M | +37.7% | -$39M | $-101.17 | - | - |
| 2015 | -$44M | -121.1% | -$41M | $-189.68 | - | - |
See TOVX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TOVX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare TOVX vs AGIO
See how TOVX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is TOVX growing earnings?
TOVX EPS of $-2.71 reflects slowing growth at +0.3%, below the 5-year CAGR of N/A. TTM net income is $-26M. Expansion rate has moderated.
What are TOVX's profit margins?
Theriva Biologics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are TOVX's earnings?
TOVX earnings data spans 1993-2024. The current earnings trend is +0.3% YoY. Historical data enables comparison across business cycles.